# Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

> **NCT05248022** · NA · UNKNOWN · sponsor: **The Central Hospital of Lishui City** · enrollment: 98 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **PROCEDURE:** Drug-eluting beads bronchial arterial chemoembolization
- **DRUG:** Programmed Cell Death Protein 1 Inhibitor

## Key facts

- **NCT ID:** NCT05248022
- **Lead sponsor:** The Central Hospital of Lishui City
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248022, "Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05248022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*